OrbiMed reveals 9.97% stake in Yarrow Bioscience after merger, plus warrants for 4.7 million shares

summarizeSummary

OrbiMed Advisors and affiliates report a 9.97% stake in Yarrow Bioscience acquired through the VYNE Therapeutics merger, including warrants for 4.7 million shares that could substantially increase ownership once exercisable.

check_boxKey Events · Ownership and Investor Activity · YARW

• OrbiMed Acquires 9.97% Stake in Merger

  As part of the VYNE Therapeutics merger on July 27, 2026, OrbiMed entities received 266,306 shares—representing 9.97% of the outstanding—making them the largest disclosed shareholder.

• Warrants for 4.7M Shares with Blocker

  OrbiMed also holds pre-funded warrants to purchase 4,668,372 shares at $0.0001 each, but a 9.99% beneficial ownership blocker prevents exercise. If the blocker were lifted, OrbiMed could control over 60% of the company.

• Board Representation via Mona Ashiya

  Direct influence over corporate decisions comes through Mona Ashiya, a member of OrbiMed Advisors, who serves on Yarrow's board of directors.

• Lock-Up Restricts Immediate Sales

  A 180-trading-day lock-up agreement prevents Ashiya from selling her shares, aligning her interests with long-term holders through early 2027.

auto_awesomeAnalysis · YARW · Life Sciences

With the VYNE Therapeutics merger closing on July 27, OrbiMed—a heavyweight in healthcare investing—now controls nearly 10% of Yarrow Bioscience. The position consists of 266,306 common shares and pre-funded warrants covering an additional 4.67 million shares, though a 9.99% blocker prevents immediate exercise. Deep institutional involvement is underscored by an OrbiMed member sitting on Yarrow's board, signaling potential sway over strategy. Because the warrants carry a $0.0001 exercise price, they are deeply in the money, creating significant overhang if the blocker is ever lifted or waived.